Reilly Financial Advisors LLC increased its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 6.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,052 shares of the company’s stock after buying an additional 316 shares during the period. Reilly Financial Advisors LLC’s holdings in Merck & were worth $324,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Macquarie Group Ltd. boosted its position in shares of Merck & by 4.1% in the fourth quarter. Macquarie Group Ltd. now owns 12,753,649 shares of the company’s stock valued at $750,807,000 after buying an additional 506,952 shares in the last quarter. RB Capital Management LLC bought a new position in shares of Merck & during the fourth quarter valued at $263,000. AE Wealth Management LLC bought a new position in shares of Merck & during the fourth quarter valued at $1,741,000. First PREMIER Bank boosted its position in shares of Merck & by 2.7% in the first quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock valued at $1,364,000 after buying an additional 570 shares in the last quarter. Finally, Blue Edge Capital LLC bought a new position in shares of Merck & during the fourth quarter valued at $744,000. Institutional investors own 73.73% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE:MRK) traded up 0.5552% during mid-day trading on Friday, hitting $62.5252. The company had a trading volume of 3,167,538 shares. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80. The firm has a 50-day moving average price of $63.46 and a 200 day moving average price of $63.80. The firm has a market capitalization of $170.53 billion, a P/E ratio of 33.8523 and a beta of 0.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.93 earnings per share. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. Merck &’s dividend payout ratio is presently 76.11%.

COPYRIGHT VIOLATION WARNING: “Reilly Financial Advisors LLC Buys 316 Shares of Merck & Company, Inc. (NYSE:MRK)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/reilly-financial-advisors-llc-buys-316-shares-of-merck-company-inc-nysemrk.html.

Several research analysts recently weighed in on MRK shares. J P Morgan Chase & Co lifted their price target on Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a research report on Thursday, May 11th. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group reiterated a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Vetr upgraded Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price target for the company in a research report on Monday, May 15th. Finally, Cowen and Company reiterated a “market perform” rating and set a $70.00 price target (up from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. Merck & currently has an average rating of “Hold” and an average price target of $69.80.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.